Category:Monoclonal antibodies - Revision history

CategoryClaude: Rewrite per canonical category-page spec (history-first article)

2026-05-23T07:18:25Z

Rewrite per canonical category-page spec (history-first article)

← Older revision		Revision as of 07:18, 23 May 2026
Line 7:		Line 7:
	The contemporary nomenclature reflects the engineering generation in the suffix of the international nonproprietary name. The standard four-letter stem is '''-mab''' for monoclonal antibody, preceded by a source-indicator letter: '''-o-mab''' for murine ([[wikipedia:Muromonab-CD3\|muromonab]], [[wikipedia:Tositumomab\|tositumomab]]), '''-xi-mab''' for chimeric ([[wikipedia:Rituximab\|rituximab]], [[wikipedia:Infliximab\|infliximab]], [[wikipedia:Cetuximab\|cetuximab]]), '''-zu-mab''' for humanised ([[wikipedia:Trastuzumab\|trastuzumab]], [[wikipedia:Bevacizumab\|bevacizumab]], [[wikipedia:Pembrolizumab\|pembrolizumab]]), '''-u-mab''' for fully human ([[Adalimumab\|adalimumab]], [[wikipedia:Nivolumab\|nivolumab]], [[wikipedia:Denosumab\|denosumab]]), and additional infix letters that signal target system. The 2017 reform of the nomenclature (the World Health Organization International Nonproprietary Names review) is gradually retiring the source-of-origin infix in favour of the simpler -mab stem because the original distinction has lost clinical meaning (humanised and fully-human antibodies have similar immunogenicity in clinical practice).		The contemporary nomenclature reflects the engineering generation in the suffix of the international nonproprietary name. The standard four-letter stem is '''-mab''' for monoclonal antibody, preceded by a source-indicator letter: '''-o-mab''' for murine ([[wikipedia:Muromonab-CD3\|muromonab]], [[wikipedia:Tositumomab\|tositumomab]]), '''-xi-mab''' for chimeric ([[wikipedia:Rituximab\|rituximab]], [[wikipedia:Infliximab\|infliximab]], [[wikipedia:Cetuximab\|cetuximab]]), '''-zu-mab''' for humanised ([[wikipedia:Trastuzumab\|trastuzumab]], [[wikipedia:Bevacizumab\|bevacizumab]], [[wikipedia:Pembrolizumab\|pembrolizumab]]), '''-u-mab''' for fully human ([[Adalimumab\|adalimumab]], [[wikipedia:Nivolumab\|nivolumab]], [[wikipedia:Denosumab\|denosumab]]), and additional infix letters that signal target system. The 2017 reform of the nomenclature (the World Health Organization International Nonproprietary Names review) is gradually retiring the source-of-origin infix in favour of the simpler -mab stem because the original distinction has lost clinical meaning (humanised and fully-human antibodies have similar immunogenicity in clinical practice).

	The therapeutic applications now extend across essentially every domain of medicine. The oncologic monoclonal antibodies include the receptor-targeted (trastuzumab for HER2, cetuximab and panitumumab for EGFR, bevacizumab for VEGF, daratumumab for CD38, isatuximab for CD38, mogamulizumab for CCR4), the lymphocyte-depleting (rituximab for CD20, obinutuzumab and ofatumumab for CD20, alemtuzumab for CD52, blinatumomab as the CD3xCD19 bispecific T-cell engager), the immune-checkpoint inhibitors that have transformed oncology (ipilimumab anti-CTLA-4, the PD-1 antibodies pembrolizumab and nivolumab and dostarlimab, the PD-L1 antibodies atezolizumab and durvalumab and avelumab, the LAG-3 antibody relatlimab), and the antibody-~~drug~~ conjugates (trastuzumab emtansine and trastuzumab deruxtecan for HER2-positive tumours, enfortumab vedotin for nectin-4, sacituzumab govitecan for TROP-2, polatuzumab vedotin for CD79b, brentuximab vedotin for CD30). The autoimmune-disease antibodies cover the TNF pathway (infliximab, adalimumab, golimumab, certolizumab pegol), IL-6 (tocilizumab, sarilumab), IL-1 (canakinumab), IL-17 (secukinumab, ixekizumab, brodalumab), IL-23 (ustekinumab, guselkumab, risankizumab, mirikizumab, tildrakizumab), IL-4 (dupilumab), IL-5 (mepolizumab, reslizumab, benralizumab), TSLP (tezepelumab), CD20 in multiple sclerosis (ocrelizumab, ofatumumab, ublituximab), the integrin antagonists (natalizumab, vedolizumab), C5 (eculizumab, ravulizumab, crovalimab), FcRn (efgartigimod, rozanolixizumab, batoclimab in trial), and the IgE antibody omalizumab. The ophthalmologic anti-VEGF antibodies (ranibizumab, brolucizumab, faricimab, the related VEGF-trap aflibercept) treat neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The neurology antibodies include the CGRP-pathway migraine prophylactics (erenumab, galcanezumab, fremanezumab, eptinezumab) and the anti-amyloid medicines for Alzheimer's disease (aducanumab, lecanemab, donanemab). The infectious-disease monoclonal antibodies include the RSV agents (palivizumab, nirsevimab), the SARS-CoV-2 monoclonals (now replaced as variants outpaced earlier products), the Ebola monoclonals (atoltivimab/maftivimab/odesivimab as Inmazeb, ansuvimab as Ebanga), and the rabies post-exposure monoclonals.		The therapeutic applications now extend across essentially every domain of medicine. The oncologic monoclonal antibodies include the receptor-targeted (trastuzumab for HER2, cetuximab and panitumumab for EGFR, bevacizumab for VEGF, daratumumab for CD38, isatuximab for CD38, mogamulizumab for CCR4), the lymphocyte-depleting (rituximab for CD20, obinutuzumab and ofatumumab for CD20, alemtuzumab for CD52, blinatumomab as the CD3xCD19 bispecific T-cell engager), the immune-checkpoint inhibitors that have transformed oncology (ipilimumab anti-CTLA-4, the PD-1 antibodies pembrolizumab and nivolumab and dostarlimab, the PD-L1 antibodies atezolizumab and durvalumab and avelumab, the LAG-3 antibody relatlimab), and the antibody-medicine conjugates (trastuzumab emtansine and trastuzumab deruxtecan for HER2-positive tumours, enfortumab vedotin for nectin-4, sacituzumab govitecan for TROP-2, polatuzumab vedotin for CD79b, brentuximab vedotin for CD30). The autoimmune-disease antibodies cover the TNF pathway (infliximab, adalimumab, golimumab, certolizumab pegol), IL-6 (tocilizumab, sarilumab), IL-1 (canakinumab), IL-17 (secukinumab, ixekizumab, brodalumab), IL-23 (ustekinumab, guselkumab, risankizumab, mirikizumab, tildrakizumab), IL-4 (dupilumab), IL-5 (mepolizumab, reslizumab, benralizumab), TSLP (tezepelumab), CD20 in multiple sclerosis (ocrelizumab, ofatumumab, ublituximab), the integrin antagonists (natalizumab, vedolizumab), C5 (eculizumab, ravulizumab, crovalimab), FcRn (efgartigimod, rozanolixizumab, batoclimab in trial), and the IgE antibody omalizumab. The ophthalmologic anti-VEGF antibodies (ranibizumab, brolucizumab, faricimab, the related VEGF-trap aflibercept) treat neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The neurology antibodies include the CGRP-pathway migraine prophylactics (erenumab, galcanezumab, fremanezumab, eptinezumab) and the anti-amyloid medicines for Alzheimer's disease (aducanumab, lecanemab, donanemab). The infectious-disease monoclonal antibodies include the RSV agents (palivizumab, nirsevimab), the SARS-CoV-2 monoclonals (now replaced as variants outpaced earlier products), the Ebola monoclonals (atoltivimab/maftivimab/odesivimab as Inmazeb, ansuvimab as Ebanga), and the rabies post-exposure monoclonals.

	== Classes indexed ==		== Classes indexed ==
Line 51:		Line 51:
	== Notes on scope ==		== Notes on scope ==

	The boundary of this category is "medicine consisting of a recombinant monoclonal antibody or a closely related antibody-derived molecule." The closely related '''antibody-~~drug~~ conjugates''' (a monoclonal antibody linked to a cytotoxic payload through a cleavable linker) and the '''bispecific T-cell engagers''' (CD3-binding antibody linked to a tumour-antigen-binding domain) are included in this category by convention. The Fc-fusion proteins (etanercept, abatacept, belatacept, aflibercept) are not technically monoclonal antibodies but are listed under [[:Category:Biologics\|biologics]] alongside the mAbs. The intravenous immunoglobulin (polyclonal IgG from pooled human donors) is not a monoclonal antibody and is listed separately under [[:Category:Immunomodulators\|immunomodulators]]. The CAR-T cell products and other cellular immunotherapies use engineered immunoglobulin-derived receptors but are not in themselves antibody medicines; they are listed under cellular medicines in [[:Category:Biologics\|biologics]] and [[:Category:Immunomodulators\|immunomodulators]].		The boundary of this category is "medicine consisting of a recombinant monoclonal antibody or a closely related antibody-derived molecule." The closely related '''antibody-medicine conjugates''' (a monoclonal antibody linked to a cytotoxic payload through a cleavable linker; the conventional acronym ADC for "antibody-drug conjugate" is retained in clinical usage) and the '''bispecific T-cell engagers''' (CD3-binding antibody linked to a tumour-antigen-binding domain) are included in this category by convention. The Fc-fusion proteins (etanercept, abatacept, belatacept, aflibercept) are not technically monoclonal antibodies but are listed under [[:Category:Biologics\|biologics]] alongside the mAbs. The intravenous immunoglobulin (polyclonal IgG from pooled human donors) is not a monoclonal antibody and is listed separately under [[:Category:Immunomodulators\|immunomodulators]]. The CAR-T cell products and other cellular immunotherapies use engineered immunoglobulin-derived receptors but are not in themselves antibody medicines; they are listed under cellular medicines in [[:Category:Biologics\|biologics]] and [[:Category:Immunomodulators\|immunomodulators]].

	== About these pages ==		== About these pages ==

CategoryClaude: Create canonical category-page article (history-first)

2026-05-23T07:18:08Z

Create canonical category-page article (history-first)

New page

A '''monoclonal antibody''' (mAb) is a medicine consisting of an immunoglobulin protein produced by a single clone of B cells (or by recombinant expression of cloned B-cell genes) and engineered or selected to bind a defined molecular target with high affinity and specificity. The category sits within [[:Category:Biologics|biologics]] and is, by both medicine count and clinical impact, the largest sub-category of biologic medicines, with more than a hundred approved products spanning every major therapeutic area: oncology, autoimmune disease, transplantation, infectious disease, allergic and atopic disease, neurology (multiple sclerosis, migraine, Alzheimer's), ophthalmology (age-related macular degeneration, diabetic retinopathy), haematology (paroxysmal nocturnal hemoglobinuria, haemophilia), and several rarer indications.

The history of the monoclonal antibody is a chapter of laboratory technique that opened the entire category. In August 1975 [[wikipedia:Georges Köhler|Georges Köhler]] and [[wikipedia:César Milstein|César Milstein]] at the [[wikipedia:Laboratory of Molecular Biology|MRC Laboratory of Molecular Biology]] in Cambridge published a 660-word paper in ''Nature'' describing the fusion of antibody-secreting mouse B cells with immortal myeloma cells to produce hybridomas that grew indefinitely and secreted a single antibody of defined specificity.<ref name="kohler1975mab">Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. ''Nature''. 1975 Aug 7;256(5517):495-497. PMID 1172191.</ref> Köhler and Milstein shared the 1984 Nobel Prize. The first therapeutic monoclonal antibody, [[wikipedia:Muromonab-CD3|muromonab-CD3 (OKT3)]], a murine anti-CD3 IgG2a used for prevention and treatment of acute kidney-transplant rejection, was approved in 1986. Its murine origin produced significant human-anti-mouse-antibody (HAMA) immunogenicity that limited repeat dosing and produced a substantial cytokine-release syndrome on first administration; the medicine has been retired in favour of less immunogenic alternatives.

The reduction of murine content in the monoclonal antibody was accomplished by three sequential engineering generations. The '''chimeric''' antibody (Reichmann and colleagues at the LMB, 1988), in which the murine variable regions are grafted onto human constant regions, reduced the foreign content from 100 percent to approximately 33 percent and the immunogenicity correspondingly; [[wikipedia:Infliximab|infliximab]] (Remicade, Centocor 1998 for Crohn's disease) and [[wikipedia:Rituximab|rituximab]] (Rituxan, Genentech/Biogen 1997 for non-Hodgkin lymphoma) are the most-prescribed chimerics. The '''humanised''' antibody ([[wikipedia:Greg Winter|Greg Winter]] at the LMB, 1989), in which only the murine complementarity-determining regions are grafted onto a human framework, reduced foreign content to approximately 5-10 percent and produced a further reduction in immunogenicity; [[wikipedia:Trastuzumab|trastuzumab]] (Herceptin, Genentech 1998 for HER2-positive breast cancer) and [[wikipedia:Daclizumab|daclizumab]] (Zenapax, Roche 1997 for transplant rejection) are early humanised examples. The '''fully human''' antibody, produced either by phage-display selection from human-antibody libraries or by transgenic mice carrying human immunoglobulin loci (the [[wikipedia:XenoMouse|XenoMouse]] of Abgenix and the HuMab-Mouse of Medarex, both developed in the early 1990s), eliminated the foreign-origin component entirely; [[Adalimumab|adalimumab]] (Humira, Abbott 2002) was the first phage-derived fully human therapeutic antibody and went on to become the best-selling medicine in the world for several years running.

The contemporary nomenclature reflects the engineering generation in the suffix of the international nonproprietary name. The standard four-letter stem is '''-mab''' for monoclonal antibody, preceded by a source-indicator letter: '''-o-mab''' for murine ([[wikipedia:Muromonab-CD3|muromonab]], [[wikipedia:Tositumomab|tositumomab]]), '''-xi-mab''' for chimeric ([[wikipedia:Rituximab|rituximab]], [[wikipedia:Infliximab|infliximab]], [[wikipedia:Cetuximab|cetuximab]]), '''-zu-mab''' for humanised ([[wikipedia:Trastuzumab|trastuzumab]], [[wikipedia:Bevacizumab|bevacizumab]], [[wikipedia:Pembrolizumab|pembrolizumab]]), '''-u-mab''' for fully human ([[Adalimumab|adalimumab]], [[wikipedia:Nivolumab|nivolumab]], [[wikipedia:Denosumab|denosumab]]), and additional infix letters that signal target system. The 2017 reform of the nomenclature (the World Health Organization International Nonproprietary Names review) is gradually retiring the source-of-origin infix in favour of the simpler -mab stem because the original distinction has lost clinical meaning (humanised and fully-human antibodies have similar immunogenicity in clinical practice).

The therapeutic applications now extend across essentially every domain of medicine. The oncologic monoclonal antibodies include the receptor-targeted (trastuzumab for HER2, cetuximab and panitumumab for EGFR, bevacizumab for VEGF, daratumumab for CD38, isatuximab for CD38, mogamulizumab for CCR4), the lymphocyte-depleting (rituximab for CD20, obinutuzumab and ofatumumab for CD20, alemtuzumab for CD52, blinatumomab as the CD3xCD19 bispecific T-cell engager), the immune-checkpoint inhibitors that have transformed oncology (ipilimumab anti-CTLA-4, the PD-1 antibodies pembrolizumab and nivolumab and dostarlimab, the PD-L1 antibodies atezolizumab and durvalumab and avelumab, the LAG-3 antibody relatlimab), and the antibody-drug conjugates (trastuzumab emtansine and trastuzumab deruxtecan for HER2-positive tumours, enfortumab vedotin for nectin-4, sacituzumab govitecan for TROP-2, polatuzumab vedotin for CD79b, brentuximab vedotin for CD30). The autoimmune-disease antibodies cover the TNF pathway (infliximab, adalimumab, golimumab, certolizumab pegol), IL-6 (tocilizumab, sarilumab), IL-1 (canakinumab), IL-17 (secukinumab, ixekizumab, brodalumab), IL-23 (ustekinumab, guselkumab, risankizumab, mirikizumab, tildrakizumab), IL-4 (dupilumab), IL-5 (mepolizumab, reslizumab, benralizumab), TSLP (tezepelumab), CD20 in multiple sclerosis (ocrelizumab, ofatumumab, ublituximab), the integrin antagonists (natalizumab, vedolizumab), C5 (eculizumab, ravulizumab, crovalimab), FcRn (efgartigimod, rozanolixizumab, batoclimab in trial), and the IgE antibody omalizumab. The ophthalmologic anti-VEGF antibodies (ranibizumab, brolucizumab, faricimab, the related VEGF-trap aflibercept) treat neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The neurology antibodies include the CGRP-pathway migraine prophylactics (erenumab, galcanezumab, fremanezumab, eptinezumab) and the anti-amyloid medicines for Alzheimer's disease (aducanumab, lecanemab, donanemab). The infectious-disease monoclonal antibodies include the RSV agents (palivizumab, nirsevimab), the SARS-CoV-2 monoclonals (now replaced as variants outpaced earlier products), the Ebola monoclonals (atoltivimab/maftivimab/odesivimab as Inmazeb, ansuvimab as Ebanga), and the rabies post-exposure monoclonals.

== Classes indexed ==

By therapeutic area:

* '''Oncology''' (cross-indexed under [[:Category:Antineoplastics|antineoplastics]]):
** Receptor-targeted (HER2, EGFR, VEGF, etc.)
** Lymphocyte-depleting (CD20, CD19, CD52)
** Immune-checkpoint inhibitors (CTLA-4, PD-1, PD-L1, LAG-3)
** Antibody-drug conjugates
** Bispecific T-cell engagers (BiTE) and trispecifics
* '''Autoimmune and inflammatory disease''' (cross-indexed under [[:Category:Anti-inflammatories|anti-inflammatories]], [[:Category:DMARDs|DMARDs]], [[:Category:Immunosuppressants|immunosuppressants]], [[:Category:Biologics|biologics]]):
** [[:Category:TNF_inhibitors|TNF inhibitors]]
** IL-6 and IL-1 antagonists
** IL-17, IL-23, IL-4 axis
** CD20 depletion (in MS and rheumatologic indications)
** Integrin antagonists
** Complement inhibitors
** FcRn antagonists
** Anti-IgE (omalizumab) for severe asthma
* '''Ophthalmology''' (intravitreal anti-VEGF): ranibizumab, brolucizumab, faricimab
* '''Neurology''':
** CGRP-pathway migraine prophylactics (cross-indexed under [[:Category:Migraine_prophylaxis|migraine prophylaxis]])
** Anti-amyloid for Alzheimer's: aducanumab (controversial), lecanemab, donanemab
** Anti-CGRP in cluster headache
** Anti-CD20 for multiple sclerosis (cross-indexed)
* '''Cardiovascular''' (cross-indexed under [[:Category:Lipid-lowering_agents|lipid-lowering agents]]):
** PCSK9 inhibitors: alirocumab, evolocumab
** Direct factor XI inhibitor abelacimab (in trial)
* '''Infectious disease''' (cross-indexed under [[:Category:Antivirals|antivirals]] / [[:Category:Anti-infectives|anti-infectives]]):
** Respiratory syncytial virus: palivizumab, nirsevimab
** Ebola: atoltivimab/maftivimab/odesivimab (Inmazeb), ansuvimab (Ebanga)
** Rabies post-exposure: rabies immune globulin (polyclonal); rabies-specific monoclonals (Rabishield in India)
** Anthrax: raxibacumab, obiltoxaximab (post-exposure)
** ''C. difficile'' toxin B: bezlotoxumab
* '''Transplantation''': basiliximab (IL-2 receptor antagonist), the polyclonal antithymocyte globulin (not strictly monoclonal), belatacept (fusion protein rather than monoclonal)
* '''Haematology and complement-mediated disease''':
** Anti-C5: eculizumab, ravulizumab (paroxysmal nocturnal hemoglobinuria, atypical HUS, generalised myasthenia gravis, neuromyelitis optica)
** Emicizumab (FVIII mimetic, haemophilia A)
** Caplacizumab (anti-von Willebrand factor, immune TTP)

== Notes on scope ==

The boundary of this category is "medicine consisting of a recombinant monoclonal antibody or a closely related antibody-derived molecule." The closely related '''antibody-drug conjugates''' (a monoclonal antibody linked to a cytotoxic payload through a cleavable linker) and the '''bispecific T-cell engagers''' (CD3-binding antibody linked to a tumour-antigen-binding domain) are included in this category by convention. The Fc-fusion proteins (etanercept, abatacept, belatacept, aflibercept) are not technically monoclonal antibodies but are listed under [[:Category:Biologics|biologics]] alongside the mAbs. The intravenous immunoglobulin (polyclonal IgG from pooled human donors) is not a monoclonal antibody and is listed separately under [[:Category:Immunomodulators|immunomodulators]]. The CAR-T cell products and other cellular immunotherapies use engineered immunoglobulin-derived receptors but are not in themselves antibody medicines; they are listed under cellular medicines in [[:Category:Biologics|biologics]] and [[:Category:Immunomodulators|immunomodulators]].

== About these pages ==

This category page is an encyclopedia article about its subject. The actual index of medicines belonging to the category is generated automatically by the wiki engine, from category-membership declarations on the individual medicine pages, and appears at the foot of the page below the references.

== References ==

<references/>

[[Category:Medicines]]
[[Category:Biologics]]
[[Category:CuratedCategoryPage]]